<- Go Home
Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 2.7T
Volume
2.7M
Cash and Equivalents
DKK 57.0B
EBITDA
DKK 133.1B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
DKK 229.1B
Profit Margin
84.66%
52 Week High
DKK 1.0K
52 Week Low
DKK 526.00
Dividend
1.60%
Price / Book Value
22.84
Price / Earnings
29.16
Price / Tangible Book Value
41.69
Enterprise Value
DKK 2.7T
Enterprise Value / EBITDA
20.29
Operating Income
DKK 125.5B
Return on Equity
88.73%
Return on Assets
22.49
Cash and Short Term Investments
DKK 74.9B
Debt
DKK 57.0B
Equity
DKK 120.5B
Revenue
DKK 270.6B
Unlevered FCF
DKK 49.7B
Sector
Pharmaceuticals
Category
N/A
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick Premium